Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOC | P08134 | 1/20 | 0.57 |
| ▸ | RHOA | P61586 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.54 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.53 |
| ▸ | BCHE | P06276 | 3/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3770493 | 0.84 | KCNK3 (0.60) | MAPTLMNASMN1; SMN2KCNK3BCHE | |
| SCHEMBL6724672 | 0.84 | MAPT (0.64) | MAPTLMNATP53SMN1; SMN2KCNK3 | |
| SCHEMBL7612923 | 0.83 | CHRNB2 (0.58) | MAPTLMNATP53SMN1; SMN2BCHE | |
| SCHEMBL3771548 | 0.81 | BCHE (0.68) | MAPTLMNATP53SMN1; SMN2BCHE | |
| SCHEMBL3771262 | 0.79 | MAPT (0.71) | MAPTLMNASMN1; SMN2BCHE | |
| SCHEMBL3777748 | 0.79 | MAPT (0.67) | MAPTLMNATP53SMN1; SMN2BCHE | |
| SCHEMBL3774815 | 0.78 | TP53 (0.58) | MAPTLMNATP53SMN1; SMN2KCNK3 | |
| SCHEMBL3774731 | 0.78 | MAPT (0.54) | MAPTLMNATP53SMN1; SMN2BCHE | |
| SCHEMBL3779966 | 0.78 | MAPT (0.54) | MAPTLMNATP53SMN1; SMN2BCHE | |
| SCHEMBL3771748 | 0.78 | PTGES (0.69) | MAPTLMNASMN1; SMN2KCNK3BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | claimed |
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | IL1B, LITAF, CYP11B1 | RHOC 4277/4885RHOA 4089/4885MAPT 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.